Mechanisms of apoptosis by the tumor suppressor Par-4

Journal of Cellular Physiology

Volumn 227, Issue 12, 2012, Pages 3715-3721

  Hebbar, Nikhil ^a   Wang, Chi ^a   Rangnekar, Vivek M ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE REGULATED PROTEIN 78; PROTEIN PROSTATE APOPTOSIS RESPONSE 4; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; ENDOPLASMIC RETICULUM STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE APOPTOSIS RESPONSE 4 GENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; SHORT SURVEY; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; RECEPTORS, THROMBIN;

EID: 84865438975     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24098     Document Type: Short Survey

References (50)

1. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. 2008. Chemoprevention of pancreatic cancer: Characterization of Par-4 and its modulation by 3, 3′ diindolylmethane (DIM). Pharm Res 25: 2117-2124.
2. Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E. 2001. Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of Par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2: 103-107.
3. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. 2009. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138: 377-388.
4. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. 2009. Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncol 48: 811-821.
5. Cang S, Liu D. 2008. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 1: 15.
6. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL, Jr., Brenner DE. 2011. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354-364.
7. Chaudhry P, Singh M, Parent S, Asselin E. 2012. Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation. Mol Cell Biol 32: 826-839.
8. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM. 1999. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18: 1205-1208.
9. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J. 1996. The product of Par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86: 777-786.
10. Diaz-Meco MT, Lallena MJ, Monjas A, Frutos S, Moscat J. 1999. Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J Biol Chem 274: 19606-19612.
11. El-Guendy N, Rangnekar VM. 2003. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 283: 51-66.
12. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. 2003. Identification of a unique core domain of Par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23: 5516-5525.
13. Fujiwara T, Oda K, Yokota S, Takatsuki A, Ikehara Y. 1988. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem 263: 18545-18552.
14. Garcia-Cao I, Duran A, Collado M, Carrascosa MJ, Martin-Caballero J, Flores JM, Diaz-Meco MT, Moscat J, Serrano M. 2005. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 6: 577-583.
15. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM. 2005. Binding and phosphorylation of Par-4 by akt is essential for cancer cell survival. Mol Cell 20: 33-44.
16. Goswami A, Qiu S, Dexheimer TS, Ranganathan P, Burikhanov R, Pommier Y, Rangnekar VM. 2008. Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity. Cancer Res 68: 6190-6198.
17. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. 2005. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25: 1146-1161.
18. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. 2001. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20: Unit 20.5. p 1-23.
19. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. 1996. A novel repressor, Par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956.
20. Johnstone RW, Tommerup N, Hansen C, Vissing H, Shi Y. 1998. Mapping of the human PAWR (Par-4) gene to chromosome 12q21. Genomics 53: 241-243.
21. Keefer LM, Piron MA, De Meyts P. 1981. Human insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptors. Proc Natl Acad Sci USA 78: 1391-1395.
22. Khan N, Adhami VM, Mukhtar H. 2010. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer 17: R39-R52.
23. Kim HJ, Hawke N, Baldwin AS. 2006. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13: 738-747.
24. Kogel D, Plottner O, Landsberg G, Christian S, Scheidtmann KH. 1998. Cloning and characterization of Dlk, a novel serine/threonine kinase that is tightly associated with chromatin and phosphorylates core histones. Oncogene 17: 2645-2654.
25. Kogel D, Reimertz C, Mech P, Poppe M, Fruhwald MC, Engemann H, Scheidtmann KH, Prehn JH. 2001. Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: Requirement of the mitochondrial apoptosis pathway. Br J Cancer 85: 1801-1808.
26. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. 1998. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17: 3247-3259.
27. Lee AS. 2007. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 67: 3496-3499.
28. Lee JI, Burckart GJ. 1998. Nuclear factor kappa B: Important transcription factor and therapeutic target. J Clin Pharmacol 38: 981-993.
29. Lee SM, Chen H, O'Halloran TV, Nguyen ST. 2009. "Clickable" polymer-caged nanobins as a modular drug delivery platform. J Am Chem Soc 131: 9311-9320.
30. Meek DW, Cox M. 2011. Induction and activation of the p53 pathway: A role for the protein kinase CK2? Mol Cell Biochem 356: 133-138.
31. Merkle D, Hoffmann R. 2011. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor. Cell Signal 23: 507-515.
32. Miller M. 2009. The importance of being flexible: The case of basic region leucine zipper transcriptional regulators. Curr Protein Pept Sci 10: 244-269.
33. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, Palacios J. 2007. Inactivation of the candidate tumor suppressor Par-4 in endometrial cancer. Cancer Res 67: 1927-1934.
34. Nambiar D, Rajamani P, Singh RP. 2011. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat Res 728: 139-157.
35. Patel VB, Misra S, Patel BB, Majumdar AP. 2010. Colorectal cancer: Chemopreventive role of curcumin and resveratrol. Nutr Cancer 62: 958-967.
36. Pavan B, Biondi C, Dalpiaz A. 2009. Adenylyl cyclases as innovative therapeutic goals. Drug Discov Today 14: 982-991.
37. Pei J, Grishin NV. 2001. GGDEF domain is homologous to adenylyl cyclase. Proteins 42: 210-216.
38. Priya R, Kumar A, Manimekalai MS, Gruber G. 2011. Conserved glycine residues in the P-loop of ATP synthases form a doorframe for nucleotide entrance. J Mol Biol 413: 657-666.
39. Qiu SG, Krishnan S, el-Guendy N, Rangnekar VM. 1999. Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 18: 7115-7123.
40. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. 2004. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6.
41. Ruzzene M, Pinna LA. 2010. Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim Biophys Acta 1804: 499-504.
42. Sayers TJ. 2011. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60: 1173-1180.
43. Sells SF, Wood DP, Jr., Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. 1994. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5: 457-466.
44. Shrestha-Bhattarai T, Rangnekar VM. 2010. Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29: 3873-3880.
45. Tortora G, Ciardiello F. 2002. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci 968: 139-147.
46. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. 2006. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160: 1-40.
47. Yoshikawa S, Kukimoto-Niino M, Parker L, Handa N, Terada T, Fujimoto T, Terazawa Y, Wakiyama M, Sato M, Sano S, Kobayashi T, Tanaka T, Chen L, Liu ZJ, Wang BC, Shirouzu M, Kawa S, Semba K, Yamamoto T, Yokoyama S. 2012. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene [Epub ahead of print].
48. Zhao Y, Rangnekar VM. 2008. Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 7: 1867-1874.
49. Zhao Y, Burikhanov R, Qiu S, Lele SM, Jennings CD, Bondada S, Spear B, Rangnekar VM. 2007. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res 67: 9276-9285.
50. Zhao Y, Burikhanov R, Brandon J, Qiu S, Shelton BJ, Spear B, Bondada S, Bryson S, Rangnekar VM. 2011. Systemic Par-4 inhibits non-autochthonous tumor growth. Cancer Biol Ther 12: 152-157.